Skip to main content
. 2022 Oct 12;14(20):4258. doi: 10.3390/nu14204258

Figure 2.

Figure 2

(a) Time course of WURSS-21 total score (p < 0.001), (b) symptom score (sum question 2–11) (p < 0.001) and (c) impact on QoL (sum question 12–20) (p < 0.01), (d) Summary table of individual items in validated WURSS-21 questionnaire indicating significance in GEE analyses per item across all doses over the full time course. The stronger beneficial impact on reducing the severity of QoL attributes in the 1.5 g/d group is mainly attributed to the response observed after d8 in a limited number of subjects. For significant items with changes > 10%, the direction of change is indicated for the 0.3 and 1.5 g/d group relative to the 0 g/d group.